Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

uticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS((R)) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a glo
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group is ... intelligence product Marketrack to now include ChinaTrack; the new ... landscape in an interactive dashboard providing detailed brand-level share ... at a hospital level. Other key capabilities ... data feed: In addition to end-user surveys of healthcare ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Lazarus Effect Closes $5 Million Financing 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated ... its,randomized, blinded, placebo-controlled phase 2 clinical trials ... rheumatoid,arthritis (RA) will be featured at the ... Rheumatology meeting, June,13-16, 2007 in Barcelona, Spain., ...
... study results confused the public about the,need and ... /PRNewswire/ -- The onslaught of,anti-stent news reports over ... that angioplasty doesn't work and its use should,decrease. ... their cardiologists about the benefits of stenting. , ...
Cached Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3To Stent or Not: Is That the Question? 2
(Date:8/1/2014)... (PRWEB) August 01, 2014 Register to join ... of the most active years on record for life sciences ... life sciences represented 22 percent of all venture dollars spent ... and achieved high valuations. , However, 2014 is proving ... recent report by Silicon Valley Bank, while life sciences IPOs ...
(Date:7/31/2014)... HEIGHTS, Ill. (August 1, 2014) Women over the ... an increased risk for obesity, greater struggles against poverty ... An article published in the August issue of ... publication of the American College of Allergy, Asthma and ... in treating asthma, and offers practical solutions to improve ...
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Ce-Classes.com has ... education course for healthcare professionals, a Systematic Review ... upon material published in the International Journal of Clinical ... created in response to a need to have accurate ... provide the best treatment possible. The material provides ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... (non-steroidal anti- inflammatory drug) treatment that can be applied directly to site of ... osteoarthritis pain * Voltaren Gel ... knees and the joints ... of the hands * Offers highly effective pain relief with ...
... Adopts InterviewDirect to ... Positions, CHERRY HILL, N.J., Oct. 22 ... telephone-based job candidate screening solutions,today announced that ... InterviewDirect service to pre-qualify job candidates for ...
... Science,Applications International Corporation (NYSE: SAI ) ... University of Kent on behalf of the United,Kingdom ... projects. Fostered by efforts of the UK ... cooperation from academia, industry and government in,collaborative research ...
... (Oct. 22, 2007)Work done in part by researchers at ... led to the discovery of two genes that cause ... The findings are published in the Oct. 21 online ... on the genetic basis for common and complex diseases. ...
... elderly patients with lung cancer has changed little despite ... The study by Harvard University, National Cancer Institute, and ... December 1, 2007 issue of CANCER, a peer-reviewed journal ... rose by less than one month between 1983 and ...
... other injuries at bay, experts say , , SUNDAY, Oct. 21 ... that Halloween is a treat for both children and adults, ... organization based in Chicago. , "We can keep Halloween safe ... Garrett, the group,s senior vice president, said in a prepared ...
Cached Medicine News:Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 2Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 3Health News:SAIC to Collaborate with UK Biometrics Institute 2Health News:SAIC to Collaborate with UK Biometrics Institute 3Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 2Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 3Health News:Spending more for lung cancer treatment did not substantially increase patients' lives 2Health News:Eye on Safety Makes Halloween Less Scary 2
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... agreement between Brook Brothers and Luxottica ... by lightweight materials and a slender ... the unique features of the style ... with classic style and affordable to ...
... Ray-Ban brand debuted in 1937 with the ... was added to Luxottica Group's brand portfolio ... show business celebrities since day one, Ray-Bans ... far the best-selling sunglasses in the world. ...
... Group has been manufacturing the Anne Klein ... Klein eyewear collections are designed for an ... wear Anne Klein eyewear identifies herself with ... refined career woman who is image-conscious and ...
Medicine Products: